Literature DB >> 24706787

T helper 17 cells play a critical pathogenic role in lung cancer.

Seon Hee Chang1, Seyedeh Golsar Mirabolfathinejad, Harshadadevi Katta, Amber M Cumpian, Lei Gong, Mauricio S Caetano, Seyed Javad Moghaddam, Chen Dong.   

Abstract

Lung cancer development is associated with extensive pulmonary inflammation. In addition, the linkage between chronic obstructive pulmonary disease (COPD) and lung cancer has been demonstrated in population-based studies. IL-17-producing CD4 helper T cells (Th17 cells) play a critical role in promoting chronic tissue inflammation. Although Th17 cells are found in human COPD and lung cancer, their role is not understood. We have thus used a mouse model of lung cancer, in which an oncogenic form of K-ras (K-ras(G12D)), frequently found in human lung cancer, is restrictedly expressed in lung epithelial cells [via Clara cell secretory protein (CCSP(cre))]. In this model, Th17 and Treg but not Th1 cells were found enriched at the tumor tissues. When CCSP(cre)/K-ras(G12D) mice were weekly challenged with a lysate of nontypeable Haemophilus influenza (NTHi), which induces COPD-type inflammation and accelerates the tumor growth, they showed greatly enhanced Th17 cell infiltration in the lung tissues. Lack of IL-17, but not IL-17F, resulted in a significant reduction in lung tumor numbers in CCSP(cre)/K-ras(G12D) mice and also those treated with NTHi. Absence of IL-17 not only resulted in reduction of tumor cell proliferation and angiogenesis, but also decreased the expression of proinflammatory mediators and reduced recruitment of myeloid cells. Depletion of Gr-1(+)CD11b(+) myeloid cells in CCSP(cre)/K-ras(G12D) mice suppressed tumor growth in lung, indicating Gr-1(+)CD11b(+) myeloid cells recruited by IL-17 play a protumor role. Taken together, our data demonstrate a critical role for Th17 cell-mediated inflammation in lung tumorigenesis and suggest a novel way for prevention and treatment of this disease.

Entities:  

Keywords:  interleukin 17; lung adenocarcinoma

Mesh:

Substances:

Year:  2014        PMID: 24706787      PMCID: PMC3992670          DOI: 10.1073/pnas.1319051111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  A risk model for prediction of lung cancer.

Authors:  Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

4.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.

Authors:  Heon Park; Zhaoxia Li; Xuexian O Yang; Seon Hee Chang; Roza Nurieva; Yi-Hong Wang; Ying Wang; Leroy Hood; Zhou Zhu; Qiang Tian; Chen Dong
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis.

Authors:  V Bandi; M A Apicella; E Mason; T F Murphy; A Siddiqi; R L Atmar; S B Greenberg
Journal:  Am J Respir Crit Care Med       Date:  2001-12-01       Impact factor: 21.405

6.  K-ras activation generates an inflammatory response in lung tumors.

Authors:  H Ji; A M Houghton; T J Mariani; S Perera; C B Kim; R Padera; G Tonon; K McNamara; L A Marconcini; A Hezel; N El-Bardeesy; R T Bronson; D Sugarbaker; R S Maser; S D Shapiro; K-K Wong
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

7.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.

Authors:  Fabrice Benchetrit; Arnaud Ciree; Virginie Vives; Guy Warnier; Alain Gey; Catherine Sautès-Fridman; François Fossiez; Nacilla Haicheur; Wolf H Fridman; Eric Tartour
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

8.  High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

Authors:  Marie Wislez; Nobukazu Fujimoto; Julie G Izzo; Amy E Hanna; Dianna D Cody; Robert R Langley; Hongli Tang; Marie D Burdick; Mitsuo Sato; John D Minna; Li Mao; Ignacio Wistuba; Robert M Strieter; Jonathan M Kurie
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 9.  Interleukin-17 family members and inflammation.

Authors:  Jay K Kolls; Anders Lindén
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

10.  Regulation of inflammatory responses by IL-17F.

Authors:  Xuexian O Yang; Seon Hee Chang; Heon Park; Roza Nurieva; Bhavin Shah; Luis Acero; Yi-Hong Wang; Kimberly S Schluns; Russell R Broaddus; Zhou Zhu; Chen Dong
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

View more
  136 in total

1.  Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.

Authors:  Heather E Metz; Julia Kargl; Stephanie E Busch; Kyoung-Hee Kim; Brenda F Kurland; Shira R Abberbock; Julie Randolph-Habecker; Sue E Knoblaugh; Jay K Kolls; Morris F White; A McGarry Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-20       Impact factor: 11.205

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.

Authors:  Shanshan Deng; Marco Ramos-Castaneda; Walter V Velasco; Michael J Clowers; Berenice A Gutierrez; Oscar Noble; Yiping Dong; Melody Zarghooni; Lucero Alvarado; Mauricio S Caetano; Shuanying Yang; Edwin J Ostrin; Carmen Behrens; Ignacio I Wistuba; Laura P Stabile; Humam Kadara; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

4.  IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer.

Authors:  Ran You; Francesco J DeMayo; Jian Liu; Sung-Nam Cho; Bryan M Burt; Chad J Creighton; Roberto F Casal; Donald R Lazarus; Wen Lu; Hui-Ying Tung; Xiaoyi Yuan; Andrea Hill-McAlester; Myunghoo Kim; Sarah Perusich; Loraine Cornwell; Daniel Rosen; Li-Zhen Song; Silke Paust; Gretchen Diehl; David Corry; Farrah Kheradmand
Journal:  Cancer Immunol Res       Date:  2018-04-13       Impact factor: 11.151

5.  IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.

Authors:  Christina Gosmann; Stephen R Mattarollo; Jennifer A Bridge; Ian H Frazer; Antje Blumenthal
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

6.  Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer.

Authors:  Joseph D Phillips; Lawrence M Knab; Nichole R Blatner; Leila Haghi; Malcolm M DeCamp; Shari L Meyerson; Michael J Heiferman; Jeffrey R Heiferman; Fotini Gounari; David J Bentrem; Khashayarsha Khazaie
Journal:  Cancer Immunol Immunother       Date:  2015-06-06       Impact factor: 6.968

7.  Tumorigenic Th17 cells in oncogenic Kras-driven and inflammation-accelerated lung cancer.

Authors:  Seon Hee Chang
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

8.  Recent Advances in Lung Immunobiology.

Authors:  Richard P Ramonell; Zohra Prasla; Charles R Terry; David A Schulman; F Eun-Hyung Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2019-12       Impact factor: 6.914

9.  Hypoxia-inducible factors: a central link between inflammation and cancer.

Authors:  Daniel Triner; Yatrik M Shah
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

10.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.